Aim: To assess amoxicillin-clavulanate (AMC) for the oral therapy of diabetic foot infections (DFIs), especially for diabetic foot osteomyelitis (DFO).
74 patients died for reasons other than DFIs after the minimal followup time. Their deaths were unrelated to infections and thus we kept them in the analyses. Fourteen patients (3%) had an immunesuppressive condition other than diabetes (dialysis, cancer, advanced cirrhosis, or medication-related). In 19% of the episodes an antibiotic therapy within the last 2 weeks influenced the intraoperative cultures.
Intraoperative cultures revealed 107 different constellations of microorganisms. The most frequent pathogens were Staphylococcus aureus (n = 273, of which 61 were methicillin-resistant), streptococci (n = 121) and gram-negatives (n = 269). According to the IDSA criteria, 5 upon which DFIs were graded, we revealed 81 mild soft tissue DFIs, 587 moderate DFIs and 126 severe DFIs, while the 339 DFO (43%) episodes mostly occurred in the forefoot (75%), with less hindfoot (8%), midfoot (9%) or ankle (9%) involvement.
| Therapy
The median number of surgical debridements per episode was one (range, 0-7 surgeries). We debrided all DFO episodes in the operating theatre, along with partial toe amputations. The median duration of postsurgical systemic antibiotic therapy was 30 days (DFO, 30 days), with a median of 5 days parentally (DFO, 6 days). We used 141 different antibiotic regimens, with changes during their treatment course. In total,
we treated 295 DFI episodes with a single antimicrobial agent, 186 with two, 125 with three, 41 with four, and 20 with five antimicrobial agents.
The most frequently prescribed drug classes (other than β-lactams)
were: quinolones (n = 204), glycopeptides (n = 120), clindamycin (n = 84), co-trimoxazole (n = 37) and rifampicin (n = 14).
Overall, we used β-lactams in 631 DFI episodes (79%) difference in a superiority design, or a 10% difference in a noninferiority analysis. A randomized trial designed for detecting smaller differences requires >1000 patients, which is clinically impracticable.
From a pharmacological point of view, all β-lactams penetrate poorly into bone. In vitro, the reported penetrations vary widely, even
for the same molecule. 8 For example, the average bone-to-serum ratios vary up to 3-fold for amoxicillin and 25-fold for clavulanic acid. 8 Even when administered parenterally, β-lactams may reveal a boneto-serum ratio as low as 20%. 8 In contrast, and clinically speaking, many case series advocate the effectiveness of oral AMC therapy for osteomyelitis, such as jaw or skull base osteomyelitis. 9 To cite further clinical examples, Sayana et al successfully treated vertebral osteomyelitis with AMC for 8 weeks. 10 Bassey reported an 83% success rate in 44 postsurgical cases of staphylococcal osteomyelitis with only 5 days of parenteral AMC, followed by 6 weeks of oral AMC. 11 Bell reported a successful therapy for 19 adult patients with high-dose oral penicillins for staphylococcal osteomyelitis. 12 Hodkin reported remission in 10 of 14 similar patients with chronic staphylococcal 15 In the antibiotic arm, oral agents were given from the start (24 cases with oral AMC 1000 mg bid; 24 cases with other oral antimicrobials). All outcomes were equal.
Moreover, several guidelines and practice-oriented expert reviews recommend oral AMC in DFI, at least in mild cases. [2] [3] [4] [5] [6] Finally, Senneville et al found that the only factor predicting success in DFOs would be the susceptibility of the organism to the antibiotic employed. No other factor, including bone antibiotic penetration, mattered. 16 In conclusion, we believe that our clinical data, along with the literature and authoritative guidelines, 5 suggest that oral AMC is a reasonable option when treating patients with DFIs and DFO.
